

concentrex®
TRENATREX[®]150

Trenbolone Acetate 150mg/ml

1 VIAL containing 10 mL

For multidose use

FOR VETERINARY USE ONLY

Therapeutic Class:
Anabolic Agent

Composition:
Each 1 ml of **TRENATREX150** contains:

- 150 mg Trenbolone Acetate
- Ethyl Oleate q.s.

Indication & Dosage:

FOR INTRAMUSCULAR USE FOR FEEDLOT CATTLE
Certain pathophysiological or catabolic processes in animals.
As anabolic after debilitating illness

The dosage for cattle is 0.55 to 2.1 mg/ of animal body weight intramuscularly. Treatment may be repeated every 2 to 3 weeks. The condition should be assessed by a veterinarian to determine the duration of treatment; however, most horses will respond with one or two treatments.

Contraindications:

In the absence of data on the effect of trenbolone acetate on immature colts and fillies, stallions, pregnant mares or brood mares during the breeding season, this drug should not be used in these animals.

Special Precautions

For feedlot cattle only. This drug is not to be administered to horses that are to be slaughtered for use in food. Keep out of reach of children.

Adverse Drug Reactions

Treatment with TRENATREX injectable (trenbolone acetate injection) may result in androgenic effects (masculinization, behavioural effects) being expressed in some animals. If these effects occur, they may persist for up to 6 to 8 weeks. No additional injections of boldenone undecylenate should be administered.

Drug Interactions

May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotrophic hormone (ACTH).

Pregnancy Category

Category X: Studies in animals beings have demonstrated foetal abnormalities or there is evidence of foetal risk.

Storage:

Store at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in a tightly-closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep out of the reach of children and away from pets.

Concentrex Laboratories N. V., Moerstraat 58, 9031, Gent, Belgium
Reg. No. Licence: 253/55-C9/2010/BE
Manufactured under WHO cGMP guidelines
www.concentrexlabs.com
Date of Preparation : 19 july 2010